Kornimate/medical-research-clean huggingface dataset:
defining musical toxicity and its effect on patient well-being

Conditions: Breast Carcinoma; Esophageal Carcinoma; Head and Neck Carcinoma; Lung Carcinoma; Malignant Brain Neoplasm; Malignant Solid Neoplasm

Summary: this study evaluates the experience of musicians who are going through cancer treatment.

primary objectives: i. describe specific musical difficulties that arise during and after cancer treatments: define "musical toxicity". ii. discover any interventions or treatments which musicians found helpful while going through cancer treatment. iii. investigate whether the priority of playing music changed through the course of cancer treatment and beyond, in relation to other priorities including cancer cure and length of life. iv. discover treatment and cancer related factors which are correlated with worse musical toxicity. outline: this is an observational study. patients are assigned to 1 of 2 groups. musical toxicity group: patients complete a questionnaire, participate in an interview and have their medical records reviewed on study. no musical toxicity group: patients have their medical records reviewed on study.

Eligibility criteria:
inclusion criteria: * \* adults ≥ 18 years or older * active or accomplished musicians * those performing in the community as part of a group or as a soloist * those teaching lessons in an individual or group setting * those for whom music teaching or performance is a primary source of income * those who play music multiple times per week * our ideal cohort will consist of an equal number of patients with the following malignancies above the diaphragm: * brain * head and neck * esophagus or lung * breast * our ideal cohort will consist of an equal number of patients who engage in the following musical endeavors: * stringed instruments * wind instruments (including woodwind and brass instruments) * keyboard instruments * vocalists exclusion criteria: * \* \< 18 years * did not regularly attempt to engage in musical endeavors during or after cancer treatment * not willing or able to complete the questionnaire or engage in a one-hour interview (i.e. limited english proficiency)
pronto: artemis in the removal of intraventricular hemorrhage in the hyper-acute phase

Conditions: Intracerebral Hemorrhage; Brain Hemorrhage; Intraventricular Hemorrhage

Summary: the purpose of this prospective, single center, single arm registry is to assess technical feasibility, peri-procedural complications, post-procedure imaging outcomes, and 30-day safety outcomes in subjects with intraventricular hemorrhages utilizing the artemis neuro evacuation device in the hyper-acute phase.

the purpose of this prospective, single center, single arm registry is to assess technical feasibility, peri-procedural complications, post-procedure imaging outcomes, and 30-day safety outcomes in subjects with intracerebral hemorrhages utilizing the artemis neuro evacuation device in the hyper-acute phase. the artemis neuro evacuation device is used for the controlled aspiration of tissue and/or fluid during surgery of the ventricular system or cerebrum in conjunction with a penumbra aspiration pump. the penumbra aspiration pump is indicated as a vacuum source for the penumbra aspiration systems. the enrollment period will end once 20 evaluable subjects have been enrolled in the registry. each subject will be in the registry for approximately 1 month.

Eligibility criteria:
inclusion criteria: 1. ≥ 18 years in age 2. patients presenting with intraventricular hemorrhage (ivh) qualifying for hematoma evacuation 3. controlled sbp ≤ 180 mmhg after initial ncct scan and prior to the initiation of the mis procedure 4. hyper-acute phase, as defined by initiation of the mis procedure no longer than 12 hours from initial ncct scan and no longer than 18 hours since time patient last known well 5. symptomatic with radiographic evidence of cerebral compression edema 6. pre-stroke mrs 0 - 2 exclusion criteria: 1. presence of tentorial herniation and/or kernohan's phenomenon 2. uncontrolled icp as defined as \> 25 mmhg for more than 30 min for 3 consecutive hours after external ventricular drain (evd) placement 3. requirement of insulin drip 4. pregnancy or positive pregnancy test (either serum or urine). women of child-bearing potential must have a negative pregnancy test prior to enrollment 5. unable to obtain consent from patient or legally authorized representative (lar) (for patients without competence) 6. presenting epilepticus that is not controlled 7. nonreversible coagulopathy (inr \> 1.4) or platelet deficiency (\< 75 x 103 cells/mm3) not able to be corrected with currently accepted treatment medications 8. contraindication to conventional angiography, cta, and mra 9. life expectancy of \< 2 months

Keywords: intraventricular hemorrhage ivh stroke
pharmacokinetics, efficacy, gametocyte carriage, birth outcomes following sulfadoxine-pyrimethamine intermittent presumptive treatment in pregnant women

Conditions: Malaria

Summary: the main purpose of this study is to compare the drug levels of sulfadoxine-pyrimethamine found when given to pregnant women for the prevention of malaria to those found in pregnant women given the same drug with artesunate for the treatment of malaria, and also with those drug levels found in non-pregnant women in other malaria treatment studies.

pregnancy increases the risk of malaria progression and complications with up to a 10-fold increase in the malaria case fatality rate in areas of low transmission. sulfadoxine-pyrimethamine (sp) is used widely in africa for the systematic intermittent presumptive, or preventive, treatment (iptp) during the second and third trimester of pregnancy and a national program of iptp with sp has been implemented recently in mozambique. there is evidence that the kinetics of several other antimalarial drugs are altered in pregnancy to the extent that doses are not adequate in pregnancy, however no published study has included a pharmacokinetic component to confirm that standard doses of sp are optimal in this vulnerable patient group. this study therefore creates the opportunity to study whether the pharmacokinetic properties of sp are altered by physiological changes that occur during pregnancy.

Eligibility criteria:
inclusion criteria: * pregnant female, older than 18 years, \> 35kg. * gestational age \> 16 weeks (fundal height \> 16cm) and below 36 weeks gestation. * documented informed consent. * lives close enough to the study site for reliable follow up and is willing to attend anc and follow-up visits regularly. exclusion criteria: * diagnoses of uncomplicated acute p. falciparum malaria parasitaemia * has received anti-malarial treatment in the past 7 days and/or sulfadoxine-pyrimethamine in the past 28 days. * known hepatic or renal impairment * has received chloramphenicol, cotrimoxazole or tetracyclines (including doxycycline) in the past 7 days or is likely to require these during the study period. * history of g6pd deficiency. * has a history of allergy to any of the study drugs (including other sulphonamides e.g. cotrimoxazole). * serious underlying disease that in the opinion of the clinic team and/or principal investigator would make the patient unsuitable for the study in terms of their safety or study analysis. * imminent delivery expected. * prior inclusion in this study.

Keywords: malaria intermittent presumptive treatment ipt pharmacokinetic efficacy gametocyte molecular markers
transanal transection and single-stapled anastomosis (ttss) in rectal cancer patients

Conditions: Rectal Cancer; Surgery

Summary: the transanal transection and single-stapled anastomosis (ttss) technique may be a valid alternative to traditional double-stapled anastomosis for low rectal cancer surgery. this study aims to compare the postoperative and functional outcomes of patients receiving ttss and traditional double-stapled anastomosis.

the transanal transection and single-stapled anastomosis (ttss) technique has become a valid alternative to the standard double-stapled anastomosis approach in the surgical treatment of low rectal cancer. recent evidence showed a significantly reduced number of anastomotic leaks in patients undergoing ttss compared with patients receiving double-stapled anastomosis, suggesting that ttss may be technically feasible and may provide a surgical advantage over the traditional double-stapled technique. however, these studies were severely limited by their single-center and retrospective nature. this study aims to confirm the retrospective findings by extending the data collection to additional countries and provide prospective data collection.

Eligibility criteria:
inclusion criteria: * adult (≥ 18 years old) patients, men and women, diagnosed with rectal cancer scheduled for elective rectal resection with total mesorectal excision (tme) with double-stapled or transanal transection and single-stapled anastomosis (ttss) approaches. * patients scheduled for open, laparoscopic, or robotic surgery. * patients preoperatively indicated for sphincter-saving procedures with or without protective-stoma. exclusion criteria: * immediate or delayed hand-sewn coloanal anastomosis. * patients requiring abdominoperineal resection (apr). patients undergoing unplanned non-reconstructive surgery will be withdrawn from the study. * patients with concurrent or previous invasive pelvic malignant tumors. patients with an intraoperative evidence of invasive pelvic malignant tumors will be withdrawn from the study.

Keywords: rectal cancer transanal transection and single-stapled anastomosis total mesorectal excision
palbociclib pharmacokinetics study in postmenopausal chinese women with er (+), her2 (-) advanced breast cancer

Conditions: Advanced Breast Cancer

Summary: as part of the global clinical development program for palbociclib, studies are planned in cancer patients in china. an assessment of palbociclib pharmacokinetics in chinese patients, as required by the chinese health authorities, is therefore warranted. in addition, safety and efficacy will be also evaluated. the single and multiple 125 mg oral dose pharmacokinetics of palbociclib will be characterized.


Eligibility criteria:
inclusion criteria: * er(+), her2(-), postmenopausal adult (ages 18-65 years, inclusive) chinese women with proven diagnosis of adenocarcinoma of the breast with evidence locoregionally recurrent or metastatic disease not amenable to resection or radiation therapy with curative intent and for whom chemotherapy is not clinically indicated. a. postmenopausal women: i. prior bilateral surgical oophorectomy; or ii. medically confirmed post-menopausal status defined as spontaneous cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause b. documentation of histologically or cytologically confirmed diagnosis of: i. er(+) breast cancer. c. documentation of her2(-) breast cancer. d. previously untreated with any systemic anti cancer therapy for their locoregionally recurrent or metastatic er+ disease. * measurable disease as defined per recist v.1.1 or bone-only disease. - tumor lesions previously irradiated or subjected to other locoregional therapy will only be deemed measurable if disease progression at the treated site after completion of therapy is clearly documented. exclusion criteria: * her2-positive tumor as defined by documentation of erbb-2 gene amplification by fish (as defined by a her2/cep17 ratio ≥2) or chromogenic in situ hybridization (cish, as defined by the manufacturer's kit instruction) or documentation of her2 overexpression by ihc (defined as ihc3+, or ihc2+ with fish or cish confirmation) based on local laboratory results * patients with advanced, symptomatic, visceral spread, that are at risk of life-threatening complications in the short term (including patients with massive uncontrolled effusions \[pleural, pericardial, peritoneal\], pulmonary lymphangitis, and over 50% liver involvement).

Keywords: palbociclib pd-0332991 pharmacokinetics breast cancer patients chinese
long-term outcomes after prolonged dual hypothermic oxygenated machine perfusion of donor livers (dhopeprolong)

Conditions: Liver Transplantation

Summary: end-ischemic dual hypothermic oxygenated machine perfusion (dhope) of human donor livers mitigates ischemia-reperfusion injury, resulting in a reduction of post-reperfusion syndrome, early allograft dysfunction and biliary complications, when compared with static cold storage. end-ischemic dhope can be used to prolong donor liver preservation time for up to 24 hours. according to ideal-d (idea, development, exploration, assessment, long term study-framework for devices), scientific evidence for prolonged dhope has currently reached stage 3. assessment of long-term outcomes after prolonged dhope preservation based on real-world data (i.e., ideal-d stage 4) is currently still lacking.

the aim of this study is to assess long-term outcomes after transplantation of donor livers preserved by prolonged hypothermic oxygenated machine perfusion (dhope-pro).

Eligibility criteria:
inclusion criteria: * adult patients (\>18 years) who underwent liver transplantation of donor livers preserved with end-ischemic dhope for \>4 hours exclusion criteria: * none

Keywords: machine preservation machine perfusion donor organ preservation hypothermic oxygenated machine perfusion donor liver machine perfusion
google health search trial

Conditions: Diagnoses Disease

Summary: there are large differences in knowledge between patients and healthcare providers (i.e. physicians, physician assistants and nurse practitioners), and there is a strong interest on the part of both industry and academia to reduce the gap in knowledge between patients and healthcare providers. currently, about 1 in 20 searches on google are health related. among internet users, 72% reported searching for health information, and among persons who use mobile phones, 31% of cell phone users and 52% of smartphone users have looked up health or medical information. oftentimes, patients will search on google or other search engines in order to find health conditions that explain their symptoms prior to visiting their healthcare provider. with the launch of google's new health search tools for mobile devices (i.e. smartphones, tablets, etc.) it is important to understand how patients use these search platforms and what their effects are on clinical encounters. the main objective of this study is to understand the accuracy of differential diagnoses generated by google searching; the investigators hypothesize that searching on google using a tablet or mobile device will be more accurate than not using any search tool, and that the new health search experience will improve accuracy over the standard search platform.


Eligibility criteria:
inclusion criteria: * adult patient \>= 18 years of age * presenting for care at urgent care or emergency department * in search of a diagnosis to explain a new symptom or group of symptoms exclusion criteria: * not literate, defined as lacking the ability to read and write (self-reported) * non-english speaking (self-reported) * not mentally competent to provide consent due to inability to understand relevant information due to deficit in intelligence (e.g. mental retardation), memory (e.g., advanced dementia or significant delirium), or attention span (e.g., attention deficit disorder (add) or mania) based on prior documentation in medical records or as judged by the researchers) * unable to use phone/tablet for any mental or physical impairment (e.g., blind) (self-reported) * exacerbation of chronic condition (self-reported)

Keywords: google knowledge panels health search online internet smartphone tablet digital mobile symptoms differential diagnosis diagnosis anxiety
evaluation of the clinical/biological characteristics, efficacy and safety of patients with malignant pleural mesothelioma, treated by immunotherapy

Conditions: Malignant Pleural Mesothelioma

Summary: the objective of this multicentre descriptive analysis is to describe the clinical and biological characteristics of patients who have received programmed cell death 1 (anti-pd1) / (pdl1) programmed death-ligand 1 (pdl1) immunotherapy outside of a clinical trial in terms of efficacy and safety.

immunotherapy is now an option in the treatment of malignant pleural mesothelioma. a french study, mesothelioma avastin plus pemetrexed-cisplatin study 2 (maps 2), prospective in 2nd line or more, found 40% and 52% disease control rate with respectively an anti-pd1 antibody or a combo of anti-pd1 and cytotoxic t-lymphocyte-associated protein 4 (anti-ctla4). safety was rather good with 14% and 26% grade 3-4 in the nivolumab and combo group respectively. thanks to this trial and data from the literature, programmed cell death 1 (anti-pd1) / (pdl1) programmed death-ligand 1 (pdl1) immunotherapy became an option in the treatment of malignant pleural mesothelioma, after validation by a multidisciplinary meeting. the objective of this multicentre descriptive analysis is to describe the clinical and biological characteristics of patients who have received anti-pd1/pdl1 immunotherapy outside of a clinical trial in terms of efficacy and safety.

Eligibility criteria:
inclusion criteria: * patient over 18 years of age, * diagnosis of malignant pleural mesothelioma affirmed by the anatomo-pathological analysis report of a histological sample of the tumour (re-read by mesopath). * patient who has received at least one injection of anti-pd1 or anti-pdl1 antibodies exclusion criteria: * explicit refusal by the patient to collect data

Keywords: immunotherapy pleura malignant pleural mesothelioma
phase ii study of pandemic influenza vaccine

Conditions: Influenza

Summary: the world health organisation has warned that an influenza pandemic is inevitable. the avian influenza h5n1 virus strain is the leading candidate to cause the next influenza pandemic. this study will test the safety and immunogenicity of a h5n1 pandemic influenza vaccine in healthy adults. the study will also assess lot to lot consistency of the pandemic influenza vaccine.


Eligibility criteria:
inclusion criteria: * healthy adults exclusion criteria: * previous vaccination with an influenza vaccine containing the h5n1 strain * history of clinically significant medical conditions * history of guillian-barre syndrome or active neurological disease

Keywords: pandemic influenza prevention vaccine prevention of pandemic influenza
oxygen saturation and caffeine post-discharge

Conditions: Prematurity

Summary: this study aims to determine normative values of oxygen saturation in late preterm infants, and evaluate the frequency of hypoxic events in infants requiring caffeine at discharge and those not requiring it.

apnea of prematurity is a common morbidity among premature infants. recent studies suggest an association between apnea and neurodevelopmental impairment. our objectives are to determine normative values of oxygen saturation in late preterm infants -reference group. in infants born 28-35 weeks requiring caffeine- study group and infants born 28-35 weeks not requiring caffeine-control group we will be evaluating the frequency of hypoxic events. recruitment time: february 2015 until december 2016. after consent a pulse oxymeter will be placed on the infant's right wrist. for those infants that will receive caffeine prior to discharge, this medication will be instituted after 12 hours of the initiation of the study and continue for the remaining of the hospitalization. for all other infants, the pulse oxymeter will be done continuously until discharge. after discharge, the recording will be done at home once a week until 46 weeks corrected age in the three groups. all the data will be reviewed by a blind observer to the groups from which that data comes. the data will be analyzed by a statistician. normative values will be developed on the reference group until 46 weeks post conceptional age. any medical problems encounter by the patients while on the study or in the following 6 months will be recorded to establish the safety of caffeine use at home and its discontinuation at 44 weeks post conceptional age.

Eligibility criteria:
inclusion criteria of infants admitted to nicu: 1. gestational age at birth of \< or = 35 weeks 2. families of infants that live in calgary 3. infants discharged home from plc or south health campus (shc) 4. decision of treating team to start caffeine 5. no episodes of clinically significant apnea for a period of 3 to 5 days prior to discharge 6. infant has access to reliable post-discharge follow up exclusion criteria of all infants: 1. active serious medical conditions other than apnea (congenital heart disease (chd), chronic lung disease (cld), symptomatic anemia). 2. congenital disorders like trisomies, genetic syndromes, midline defects, metabolic disorders.

Keywords: caffeine use normative data
parecoxib in renal colic

Conditions: Colic

Summary: this is a phase iii, multicenter, randomized, single blind study designed to evaluate the efficacy and tolerability of a single dose of parecoxib compared with diclofenac in the treatment of acute pain due to renal colic.

this study was prematurely discontinued may 3, 2004 due to slow recruitment. the decision to terminate the trial was not based on any safety concerns.

Eligibility criteria:
inclusion criteria: * diagnosis of renal colic; * baseline pain \> 50 mm on vas; exclusion criteria: * evidence of neoplasm or any other severe disease of any organ, including any psychiatric illness; * active gi disease (e.g. crohn's disease or ulcerative colitis) or any evidence of concomitant disease which may lead to early termination of the study